Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 85, Issue 5, Pages 535-538Publisher
WILEY
DOI: 10.1038/clpt.2009.9
Keywords
-
Categories
Ask authors/readers for more resources
The codevelopment of predictive biomarkers along with therapeutic agents, particularly in oncology, is becoming increasingly important. This approach presents both substantial opportunities and challenges. We illustrate these by reviewing some specific recent examples relating to the development of anticancer drugs targeting the HER family of cell surface receptors. We argue that ultimate success may require significant changes to the current approach to drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available